Estadístiques de Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular Llymphoma after first-line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial
Visites totals
| views | |
|---|---|
| Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular Llymphoma after first-line immunochemotherapy: results of the RBMDGELTAMO08 phase II trial | 172 |
Visites totals per mes
| views | |
|---|---|
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| penalver-cam-resp.pdf | 98 |
| penalver-cam-resp.pdf(legacy) | 90 |
Vistes principals per país
| views | |
|---|---|
| United States | 104 |
| China | 28 |
| Spain | 8 |
| Germany | 7 |
| Ireland | 7 |
| Sweden | 6 |
| Belgium | 5 |
| South Korea | 2 |
| Czechia | 1 |
| Mongolia | 1 |
| Malaysia | 1 |
| Netherlands | 1 |
| Turkey | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Shenzhen | 28 |
| San Ramon | 18 |
| Boardman | 13 |
| Fairfield | 11 |
| Dublin | 7 |
| Ann Arbor | 6 |
| Tustin | 6 |
| Barcelona | 5 |
| Menlo Park | 5 |
| Ashburn | 4 |
| Alicante | 2 |
| Daejeon | 2 |
| Mountain View | 2 |
| Sacramento | 2 |
| San Diego | 2 |
| Amstelveen | 1 |
| Cambridge | 1 |
| Cupertino | 1 |
| Don Benito | 1 |
| Istanbul | 1 |
| Redwood City | 1 |
| Shah Alam | 1 |
| Sükhbaatar | 1 |